- AstraZeneca (AZN, Financial) sees positive momentum for Imfinzi Immunotherapy in Europe following Phase 3 trial success.
- Analysts anticipate a potential 42.53% price increase, signaling optimism in AstraZeneca's market prospects.
- GuruFocus estimates a 24.84% upside, highlighting AZN's fair valuation potential.
AstraZeneca's European Milestone with Imfinzi
AstraZeneca (AZN) has achieved a significant step forward as the European Medicines Agency's expert panel endorses its Imfinzi immunotherapy. This approval is part of a comprehensive treatment regimen targeting muscle-invasive bladder cancer. The recommendation is grounded on promising outcomes from the NIAGARA Phase 3 trial, positioning the company closer to securing marketing authorization by the European Commission.
Wall Street Analysts Forecast
In an analysis by 11 market experts, AstraZeneca PLC (AZN, Financial) has been assigned an average one-year price target of $100.36. This figure represents an encouraging upside potential of 42.53% from its current trading price of $70.41. The range of estimates spans from a low of $67.00 to a high of $233.46. For an in-depth look at these insights, visit the AstraZeneca PLC (AZN) Forecast page.
From a consensus view across 13 brokerage firms, AstraZeneca PLC garners an average brokerage recommendation standing at 1.8, which translates to an "Outperform" rating. With the recommendation scale ranging from 1 (Strong Buy) to 5 (Sell), this positions AZN favorably among investors.
Evaluating AstraZeneca's Market Value
According to GuruFocus' sophisticated valuation metrics, AstraZeneca PLC's (AZN, Financial) projected GF Value over the next year is $87.90. This valuation implies a notable upside of 24.84% relative to the current price of $70.41. The GF Value is derived from historical trading multiples and predictive analysis of future business performance. Investors can explore more comprehensive data on the AstraZeneca PLC (AZN) Summary page.
